26.11.2012 Views

Guidelines for ATC classification and DDD assignment - WHOCC

Guidelines for ATC classification and DDD assignment - WHOCC

Guidelines for ATC classification and DDD assignment - WHOCC

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

D. Principles <strong>for</strong> reviewing <strong>and</strong> changing <strong>DDD</strong><br />

As the dosages used may change over time, it will always be necessary to make<br />

some alterations. The International Working Group <strong>for</strong> Drug Statistics<br />

Methodology may review a <strong>DDD</strong> whenever the Group finds it appropriate.<br />

Changes of <strong>DDD</strong>s should be kept to a minimum <strong>and</strong> avoided as far as possible.<br />

Too many alterations will always be disadvantageous <strong>for</strong> long-term studies on drug<br />

utilization. Be<strong>for</strong>e alterations are made, difficulties arising <strong>for</strong> the users are<br />

weighed against the benefits achieved by the alteration.<br />

- The same principles used to assign new <strong>DDD</strong>s also apply when <strong>DDD</strong>s are<br />

reviewed.<br />

- Changes are generally not made unless they are at least in the order of 50 %.<br />

This rule is not used <strong>for</strong> the three year revision of <strong>DDD</strong>s, where smaller<br />

alterations are allowed. Further, minor alterations are allowed <strong>for</strong> important<br />

drugs, which are frequently used (e.g. the <strong>DDD</strong> <strong>for</strong> cimetidine was changed from<br />

1.0 g to 0.8 g).<br />

<strong>DDD</strong> review after three years<br />

All newly assigned <strong>DDD</strong>s are reviewed during the third year after inclusion in the<br />

<strong>ATC</strong> Index with <strong>DDD</strong>s. The <strong>DDD</strong>s are reviewed at the first semi-annual meeting of<br />

the International Working Group <strong>for</strong> Drug Statistics Methodology. The following<br />

are considered:<br />

- Recommended dosages as listed in drug catalogues in different countries <strong>and</strong>/or<br />

published in peer reviewed scientific journals or major international textbooks.<br />

- Data on prescribed daily doses (PDDs) from a range of countries. Figures<br />

showing the prescribed daily dose (PDD) are important when reviewing an<br />

assigned <strong>DDD</strong>. Usually more data concerning PDDs are available after a three<br />

years period than at the time of marketing.<br />

- Established main indication <strong>and</strong> therapy profile of the preparation (i.e. has the<br />

main indication changed?)<br />

- Existing <strong>DDD</strong>s in the <strong>ATC</strong> group.<br />

- Written objections to the <strong>DDD</strong> which have been received.<br />

When reviewing combination products, changes in the <strong>DDD</strong>s <strong>for</strong> the different<br />

active ingredients are an important consideration.<br />

29

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!